tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 May 28;9(1):93.
doi: 10.1038/s41541-024-00886-0. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
Muriel Aguilar-Bretones[SUP] #[/SUP][SUP] 1 [/SUP], Yvette den Hartog[SUP] #[/SUP][SUP] 2 [/SUP], Laura L A van Dijk[SUP] #[/SUP][SUP] 1 [/SUP], S Reshwan K Malahe[SUP] 2 [/SUP], Marjolein Dieterich[SUP] 2 [/SUP], Héctor Tejeda Mora[SUP] 2 [/SUP], Yvonne M Mueller[SUP] 3 [/SUP], Marion P G Koopmans[SUP] 1 [/SUP], Marlies E J Reinders[SUP] 2 [/SUP], Carla C Baan[SUP] 2 [/SUP], Gijsbert P van Nierop[SUP] #[/SUP][SUP] 4 [/SUP], Rory D de Vries[SUP] #[/SUP][SUP] 5 [/SUP]; RECOVAC Consortium
Collaborators, Affiliations
Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.
. 2024 May 28;9(1):93.
doi: 10.1038/s41541-024-00886-0. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
Muriel Aguilar-Bretones[SUP] #[/SUP][SUP] 1 [/SUP], Yvette den Hartog[SUP] #[/SUP][SUP] 2 [/SUP], Laura L A van Dijk[SUP] #[/SUP][SUP] 1 [/SUP], S Reshwan K Malahe[SUP] 2 [/SUP], Marjolein Dieterich[SUP] 2 [/SUP], Héctor Tejeda Mora[SUP] 2 [/SUP], Yvonne M Mueller[SUP] 3 [/SUP], Marion P G Koopmans[SUP] 1 [/SUP], Marlies E J Reinders[SUP] 2 [/SUP], Carla C Baan[SUP] 2 [/SUP], Gijsbert P van Nierop[SUP] #[/SUP][SUP] 4 [/SUP], Rory D de Vries[SUP] #[/SUP][SUP] 5 [/SUP]; RECOVAC Consortium
Collaborators, Affiliations
- PMID: 38806532
- PMCID: PMC11133345
- DOI: 10.1038/s41541-024-00886-0
Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.